Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Heartflow's AI-Powered Coronary Plaque Analysis Advances with FDA Clearance and Expanded Insurance Coverage

Heartflow's AI-Powered Coronary Plaque Analysis Advances with FDA Clearance and Expanded Insurance Coverage

Heartflow, a leading medtech company specializing in cardiovascular diagnostics, has made significant strides in the field of coronary plaque analysis with its latest artificial intelligence (AI) platform. The company recently secured FDA clearance for an updated version of its AI software, which offers enhanced capabilities in analyzing coronary artery plaque buildup. This development comes alongside expanded insurance coverage, marking a pivotal moment for both the company and the field of cardiovascular imaging.

NoahAI News9/25/2025
AI Scheduling Agents Revolutionize Outpatient Clinic Operations

AI Scheduling Agents Revolutionize Outpatient Clinic Operations

Nashville-based startup UnityAI has launched a new AI platform designed to streamline scheduling and patient communication for outpatient clinics. This development comes amid a growing trend of AI-powered solutions in healthcare administration, with several companies securing significant funding to expand their offerings.

NoahAI News9/25/2025
Acadia Halts Development of Prader-Willi Syndrome Drug After Phase 3 Failure

Acadia Halts Development of Prader-Willi Syndrome Drug After Phase 3 Failure

Acadia Pharmaceuticals has announced the discontinuation of its experimental drug ACP-101 for the treatment of hyperphagia in Prader-Willi syndrome following disappointing results from a Phase 3 clinical trial. The decision marks a significant setback for the company and reshapes the competitive landscape in the rare disease space.

NoahAI News9/25/2025
Future Family Appoints New CEO, Expands IVF Financing Options

Future Family Appoints New CEO, Expands IVF Financing Options

Future Family, a leading in vitro fertilization (IVF) financing platform, has announced the appointment of Alden Romney as its new CEO. The company, which has extended over $200 million in financing to more than 10,000 families since its inception in 2016, is poised for its next phase of growth under Romney's leadership.

NoahAI News9/25/2025
Lantheus and GE HealthCare Strike Deal for Prostate Cancer PET Tracer in Japan

Lantheus and GE HealthCare Strike Deal for Prostate Cancer PET Tracer in Japan

Lantheus has entered into an agreement with GE HealthCare, granting the latter rights to its blockbuster prostate cancer PET imaging agent, Pylarify, in Japan. This strategic move aims to expand the reach of the diagnostic tool in key international markets, leveraging GE HealthCare's recent acquisition of Nihon Medi-Physics (NMP), a leading radiopharmaceutical provider in Japan.

NoahAI News9/25/2025
Biopharma Deal Trends: Upfront Payments Rise as Earnout Potential Declines

Biopharma Deal Trends: Upfront Payments Rise as Earnout Potential Declines

In a shifting landscape of pharmaceutical industry dealmaking, recent data reveals a notable trend: while the average earnout potential in biopharma deals has decreased over the past five years, upfront payments have seen a steady increase since 2017. This development, highlighted in a recent analysis by SRS Acquiom, a U.S. loan agency and post-closing shareholder representative, offers insights into the evolving dynamics of industry partnerships and acquisitions.

NoahAI News9/25/2025
Big Pharma Trims Workforce to Boost Efficiency

Big Pharma Trims Workforce to Boost Efficiency

Bristol Myers Squibb (BMS) continues its sweeping cost-cutting initiative, announcing an additional $2 billion in savings planned through 2027. This comes on top of an ongoing program targeting $1.5 billion in cuts by the end of 2025. The dramatic upheaval has resulted in multiple rounds of layoffs, with BMS disclosing plans to cut 516 jobs in Lawrenceville, New Jersey, bringing the total number of affected employees in that area to 806 this year alone.

NoahAI News9/25/2025
Indian Generics Makers Set to Revolutionize HIV Prevention with Affordable Yeztugo

Indian Generics Makers Set to Revolutionize HIV Prevention with Affordable Yeztugo

In a groundbreaking development for global HIV prevention, Indian generic pharmaceutical companies are poised to produce and distribute significantly cheaper versions of Gilead Sciences' twice-yearly HIV pre-exposure prophylaxis (PrEP) drug, Yeztugo (lenacapavir). This initiative, supported by international health organizations and philanthropic foundations, aims to dramatically improve access to long-acting PrEP in low- and middle-income countries.

NoahAI News9/25/2025
Sparrow Pharmaceuticals Secures $95M Series B for Diabetes Treatment

Sparrow Pharmaceuticals Secures $95M Series B for Diabetes Treatment

Sparrow Pharmaceuticals, a Portland, Oregon-based biotech company, has announced a significant boost to its diabetes research efforts with a $95 million series B funding round. The investment, led by RA Capital Management and Forbion, with participation from existing investors OrbiMed, RiverVest, and US Venture Partners, will primarily support the ongoing phase 2b trial of the company's oral small molecule, clofutriben.

NoahAI News9/25/2025
Pfizer's Big Move in Obesity, FDA's Autism Initiative, and Psychedelics' Revival: A Week of Pharmaceutical Breakthroughs

Pfizer's Big Move in Obesity, FDA's Autism Initiative, and Psychedelics' Revival: A Week of Pharmaceutical Breakthroughs

In a week marked by significant developments across the pharmaceutical landscape, industry giants and startups alike have made waves with acquisitions, regulatory initiatives, and therapeutic advancements. From obesity treatments to rare disease approvals, the sector continues to evolve rapidly, promising new horizons in patient care and corporate strategy.

NoahAI News9/25/2025
Cardiosense Appoints New CEO to Lead Growth Following FDA Clearance

Cardiosense Appoints New CEO to Lead Growth Following FDA Clearance

Cardiosense, a rising player in the wearable medical device industry, has announced significant changes to its leadership team as it prepares to capitalize on recent regulatory success and expand its market presence.Cardiosense has appointed Eric Meizlish as its new Chief Executive Officer, replacing co-founder Amit Gupta, who will transition to the role of Chief Strategy Officer. Meizlish brings a wealth of experience in scaling healthtech companies, having previously served as co-founder and president of Lumere, a health data and analytics company acquired by Global Healthcare Exchange in 2020. Most recently, Meizlish held the position of CEO at Prendio-BioProcure, a life science procurement platform.

NoahAI News9/25/2025
Hengrui Pharma Expands Global Reach with $1.1B ADC Deal

Hengrui Pharma Expands Global Reach with $1.1B ADC Deal

Jiangsu Hengrui Pharmaceuticals continues its aggressive expansion strategy with a potential $1.1 billion licensing deal for its HER2 antibody-drug conjugate (ADC) trastuzumab rezetecan. The agreement, announced on September 24, 2025, grants certain rights to a subsidiary of India's Glenmark Pharmaceuticals, focusing on emerging markets while excluding major regions such as the U.S., Canada, Europe, Japan, and greater China.

NoahAI News9/25/2025
«1...484950...67»